GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to provide a corporate update
and report its third-quarter 2018 financial results on Friday, November 2, 2018, at 8:30 a.m. ET.
The dial-in number for the conference call is (844) 413-7154 (U.S. and Canada) or (216) 562-0466 (international) with
passcode 9176334. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events &
Presentations” section of the GlycoMimetics website at
www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following
the call.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly-owned drug candidate, GMI-1271 (uproleselan), an E-selectin antagonist, was evaluated in a Phase 1/2
clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of
multiple myeloma. The FDA granted uproleselan Breakthrough Therapy designation for the treatment of adult acute myeloid
leukemia (AML) patients with relapsed/refractory disease. GlycoMimetics is also conducting a Phase 1 clinical trial with a
third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the clinical development of the company’s drug candidates,
including the expected timing of completion of clinical trials and the presentation of clinical data. Actual results may differ
materially from those in these forward-looking statements. For a further description of the risks associated with these statements,
as well as other risks facing GlycoMimetics, please see the risk factors described in the company’s annual report on Form 10-K to
be filed with the U.S. Securities and Exchange Commission (SEC) on March 6, 2018, and other filings GlycoMimetics makes with the
SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no
obligation to update or revise these statements, except as may be required by law.
GlycoMimetics, Inc.
Investor Contact:
Shari Annes, 650-888-0902
sannes@annesassociates.com
or
Media Contact:
Jamie Lacey-Moreira, 410-299-3310
jamielacey@presscommpr.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181026005014/en/